Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
Biomolecules · 26.04.2023 · 13 (5) · 752
DOI: 10.3390/biom13050752 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 26.04.2023. Verfasst von Sabrina Scilletta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The classic description of diabetic kidney disease (DKD) involves progressive stages of glomerular hyperfiltration, microalbuminuria, proteinuria, and a decline in the estimated glomerular filtration rate (eGFR), leading to dialysis. In recent years, this concept has been increasingly challenged as evidence suggests that DKD presents more heterogeneously. Large studies have revealed that eGFR decline may also occur independently from the development of albuminuria. This concept led to the identification of a new DKD phenotype: non-albuminuric DKD (eGFR < 60 mL/min/1.73 m2, absence of albuminuria), whose pathogenesis is still unknown. However, various hypotheses have been formulated, the most likely of which is the acute kidney injury-to-chronic kidney disease (CKD) transition, with prevalent tubular, rather than glomerular, damage (typically described in albuminuric DKD). Moreover, it is still debated which phenotype is associated with a higher cardiovascular risk, due to contrasting results available in the literature. Finally, much evidence has accumulated on the various classes of drugs with beneficial effects on DKD; however, there is a lack of studies analyzing the different effects of drugs on the various phenotypes of DKD. For this reason, there are still no specific guidelines for therapy in one phenotype rather than the other, generically referring to diabetic patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Catania, 95122 Catania, Italy.
ORCID-Profile: Sabrina Scilletta, Maurizio Di Marco, Nicoletta Miano, Agnese Filippello, Stefania Di Mauro, Alessandra Scamporrino, Giosiana Bosco, Roberto Scicali, Salvatore Piro
Zitieren
APA
Scilletta, S., Di Marco, M., Miano, N., Filippello, A., Di Mauro, S., Scamporrino, A., Musmeci, M., Coppolino, G., Di Giacomo Barbagallo, F., Bosco, G., Scicali, R., Piro, S., Purrello, F., & Di Pino, A. (2023). Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. Biomolecules, 13(5), 752. https://doi.org/10.3390/biom13050752
Vancouver
Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, Scamporrino A, et al. Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. Biomolecules. 2023;13(5):752. doi:10.3390/biom13050752
BibTeX
@article{Scilletta2023,
author = {Scilletta, Sabrina and Di Marco, Maurizio and Miano, Nicoletta and Filippello, Agnese and Di Mauro, Stefania and Scamporrino, Alessandra and Musmeci, Marco and Coppolino, Giuseppe and Di Giacomo Barbagallo, Francesco and Bosco, Giosiana and Scicali, Roberto and Piro, Salvatore and Purrello, Francesco and Di Pino, Antonino},
title = {Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {5},
pages = {752},
doi = {10.3390/biom13050752}
}
EUVIMED